HEL · ORNBV.HE
Orion Oyj
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
Loading market information…
HEL · NANOFH.HE · EUR
Stock price, earnings
Quote as of Oct 30, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Nanoform Finland Oyj’s quoted price sits in the lower half of its reported 52-week range, 34.98% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanoform Finland Oyj’s next earnings report is currently expected on Nov 19, 2026, with estimated earnings per share of -€0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanoform Finland Oyj’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Helsinki, Finland-based Nanoform Finland Oyj provides advanced nanotechnology and drug particle engineering solutions for the pharmaceutical sector across Europe and the United States. The company specializes in the production of nanoparticles, utilizing its exclusive "controlled expansion of supercritical solutions" technology, which aids its clients in their development processes. Nanoform was established in 2008.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:52 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 20, 2025 | -€0.07-8.33% vs estimate | €878.00K-20.18% vs estimate |
|---|
| Q4 2024 | Feb 27, 2025 | -€0.06-50.0% vs estimate | €750.00K-44.44% vs estimate |
|---|
| Q3 2024 | Nov 18, 2024 | -€0.06-20.0% vs estimate | €785.00K-24.52% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
€6.04+€0.03 (+0.5%)
Terveystalo Oyj’s quoted price sits in the lower half of its reported 52-week range, 42.03% below the high.
€10.38-€0.02 (-0.19%)
Revenio Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.15% below the high.
€8.80-€0.07 (-0.79%)
Nexstim Plc’s quoted price sits in the lower half of its reported 52-week range, 42.67% below the high.
€1.01-€0.01 (-0.99%)
Modulight Oyj’s quoted price sits in the lower half of its reported 52-week range, 27.17% below the high.
€2.11-€0.04 (-1.86%)
Biohit Oyj’s quoted price sits in the lower half of its reported 52-week range, 44.18% below the high.
€1.18-€0.02 (-1.67%)
Herantis Pharma Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.89% below the high.
€1.41+€0.04 (+3.07%)
Optomed Oyj’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
